<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Parenteral and oral opioid analgesics for acute perioperative pain in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Parenteral and oral opioid analgesics for acute perioperative pain in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Parenteral and oral opioid analgesics for acute perioperative pain in adults</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="10%"></colgroup><colgroup width="20%"></colgroup><colgroup span="2" width="10%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug (United States brand name)</td> <td class="subtitle1">Approximate equianalgesic doses*</td> <td class="subtitle1">Sample initial dose for opioid-naïve adult<sup>¶</sup></td> <td class="subtitle1">Serum half-life (in hours)</td> <td class="subtitle1">Duration of analgesic effect (in hours)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Parenteral opioids</td> </tr> <tr class="divider_bottom"> <td class="indent1">Fentanyl (Sublimaze)</td> <td>100 mcg IV</td> <td>25 to 50 mcg for moderate pain or 50 to 100 mcg for more severe pain IV/subcutaneous; repeat every two to five minutes as needed until adequate pain relief</td> <td>7 to 12</td> <td>0.5 to 1 (IV)<br/> 1 to 2 (subcutaneous)</td> <td> <ul> <li>Fentanyl does not release histamine and may therefore be preferred in the presence of hemodynamic instability or bronchospasm. </li> <li>Potential for drug interactions as it is hepatically metabolized by CYP3A4.<sup>Δ</sup> </li> <li>Duration of effect increases after repeated use. </li> <li>May be used for PCA, less commonly than hydromorphone and morphine. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Hydromorphone (Dilaudid)</td> <td>1.5 mg IV</td> <td>0.2 to 0.5 mg IV; repeat every five minutes as needed until adequate pain relief, then 0.2 to 0.5 mg IV every three to four hours as needed</td> <td>2 to 3</td> <td>3 to 4</td> <td> <ul> <li>Lower potential for drug interactions as it is hepatically metabolized primarily by glucuronidation. </li> <li>Use reduced dose in renal and/or hepatic impairment. </li> <li>May be used for PCA. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Morphine (Infumorph, others)</td> <td>10 mg IV</td> <td>1 to 3 mg IV; repeat every five minutes as needed until adequate pain relief; then 1 to 3 mg IV every three to four hours as needed</td> <td>2 to 3</td> <td>4 to 5</td> <td> <ul> <li>Lower potential for drug interactions as it is hepatically metabolized primarily by glucuronidation. </li> <li>In patients with renal impairment, clearance of active metabolites that contribute to hyperalgesia and neuroexcitation is decreased; hydromorphone or fentanyl may be preferred. </li> <li>Histamine release and vagally mediated venodilation, hypotension, and bradycardia can be significant. </li> <li>May be used for PCA. </li> <li>Subcutaneous not recommended due to local tissue irritation. </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="6">Oral immediate-release opioids</td> </tr> <tr class="divider_bottom"> <td class="indent1">Codeine</td> <td>200 mg orally</td> <td>15 to 60 mg orally every four to six hours as needed</td> <td>2 to 4</td> <td>4 to 6</td> <td> <ul> <li>Potential for drug interactions as it is hepatically metabolized by CYP2D6 to active metabolite (ie, morphine). </li> <li>Analgesic and adverse effects are unpredictable because rate of conversion to morphine is genetically determined by polymorphic CYP2D6 enzyme. Generally not recommended for this reason. </li> <li>Oral immediate-release preparations are also available in combinations with acetaminophen (eg, Tylenol #3); acetaminophen component dose limits apply to combinations. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Hydrocodone (immediate-release only available in US in combination products, eg, Vicodin, Lorcet, others)</td> <td>30 mg orally</td> <td>5 to 10 mg orally every six hours as needed</td> <td>3 to 4</td> <td>4 to 8</td> <td> <ul> <li>Hepatically metabolized by CYP2D6 and 3A4 to active (ie, hydromorphone) and inactive metabolites. </li> <li>Oral immediate-release preparations are only available in United States in combinations with acetaminophen or ibuprofen; nonopioid component dose limits apply. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Hydromorphone (Dilaudid)</td> <td>7.5 mg orally</td> <td>2 to 4 mg orally every four hours as needed</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Refer to comments for parenteral hydromorphone above. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Morphine</td> <td>30 mg orally</td> <td>15 to 30 mg orally every four hours as needed</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Refer to comments for parenteral morphine above. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Oxycodone (Oxy-IR, Roxicodone, others)</td> <td>20 mg orally</td> <td>5 to 10 mg orally every four to six hours as needed</td> <td>2 to 3</td> <td>3 to 6</td> <td> <ul> <li>Hepatically metabolized by CYP2D6 and 3A4 to active and inactive metabolites. </li> <li>Oral immediate-release preparations are also available in combinations with acetaminophen, aspirin, or ibuprofen; nonopioid component dose limits apply to combinations. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Oxymorphone (Opana)</td> <td>10 to 15 mg orally</td> <td>5 to 10 mg orally every four to six hours as needed</td> <td>7 to 9</td> <td>3 to 6</td> <td> </td> </tr> <tr> <td class="indent1">Tramadol (Ultram, others)</td> <td>Not established</td> <td>50 to 100 mg every four to six hours as needed</td> <td>6 to 9 (includes active metabolite)</td> <td>4 to 6</td> <td> <ul> <li>Multiple mechanisms of action: Weak mu-opioid agonist and reuptake inhibitor of norepinephrine and serotonin. </li> <li>Risk of drug interactions. </li> <li>Use reduced dose for moderate renal or hepatic impairment. </li> <li>Not recommended in severe organ impairment or if risk for seizures. </li> <li>Effects not fully reversed by naloxone. </li> <li>Also available in combinations with acetaminophen; dose limits apply. </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Initial IV titration and continuous infusion of opioids for acute perioperative pain should only be administered in a closely monitored setting with pulse oximetry and end-tidal carbon dioxide monitoring capabilities. For dosing of continuous infusion delivery, refer to UpToDate content on pain control in critically ill patients.<br/>Oral opioids should be prescribed starting with the minimum dose needed to alleviate pain and after maximizing non-opioid analgesic options. Extended-release preparations of oral opioids are generally not recommended for acute pain.<br/>For PCA doses, refer to UpToDate content on management of acute perioperative pain.</div><div class="graphic_footnotes">IV: intravenous; CYP: cytochrome P-450 metabolism; PCA: patient controlled analgesia; US: United States.<br/>* Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents.<br/>¶ Lower doses may be effective for patients who simultaneously receive non-opioid analgesics. A dose reduction of approximately 50% and a reduced frequency is warranted for older or debilitated adults or patients with impaired liver or kidney functioning, low cardiac output, or respiratory compromise.<br/>Δ A list of inhibitors and inducers of CYP3A4 metabolism is available as a separate table in UpToDate.</div><div class="graphic_reference">Courtesy of Edward Mariano, MD.<br/>Additional data from: 
<ol>
<li>Lexicomp Online. Copyright © 1978-2023 Lexicomp, Inc. All Rights Reserved.</li></ol></div><div id="graphicVersion">Graphic 113048 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
